Bioatla Inc reports results for the quarter ended in September 30 - Earnings Summary

Bioatla

08/11/2024 05:15

* Bioatla Inc  BCAB.OQ  reported a quarterly adjusted loss
of 22
cents​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of -70 cents.  The mean expectation of four analysts for the
quarter was for a loss of 36 cents per share. Wall Street
expected results to range from -38 cents to -34 cents per share.
    * Revenue was $11.00 million​; analysts expected zero. 
    * Bioatla Inc's reported EPS for the quarter was a loss
of 22
cents​.
    * The company reported a quarterly loss of $10.59 million.
    * Bioatla Inc shares had risen by 26.1% this quarter and
lost 9.8%
so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 5.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Bioatla Inc is
$10.00 
This summary was machine generated from LSEG data November 8 at
05:15 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.36          -0.22          Beat
 Jun. 30 2024      -0.44          -0.44          Met
 Mar. 31 2024      -0.54          -0.48          Beat
 Dec. 31 2023      -0.79          -0.56          Beat